Edition:
United States

Veracyte Inc (VCYT.OQ)

VCYT.OQ on NASDAQ Stock Exchange Global Market

22.47USD
3:57pm EDT
Change (% chg)

$0.43 (+1.93%)
Prev Close
$22.04
Open
$22.21
Day's High
$22.86
Day's Low
$22.07
Volume
83,240
Avg. Vol
151,417
52-wk High
$22.86
52-wk Low
$5.36

Latest Key Developments (Source: Significant Developments)

Veracyte Says It Receives Final Medicare Coverage Policy for Envisia Genomic Classifier
Monday, 4 Mar 2019 04:25pm EST 

March 4 (Reuters) - Veracyte Inc ::VERACYTE - RECEIVED A FINAL MEDICARE LOCAL COVERAGE DETERMINATION FOR ENVISIA GENOMIC CLASSIFIER; WILL BECOME EFFECTIVE APRIL 1, 2019.  Full Article

Veracyte Inc Q4 Net Loss Per Common Share $0.24
Tuesday, 27 Feb 2018 04:00pm EST 

Feb 27 (Reuters) - Veracyte Inc ::VERACYTE ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS, PROVIDES 2018 FINANCIAL OUTLOOK.SEES FY 2018 REVENUE $81 MILLION TO $83 MILLION.QTRLY ‍REVENUE WAS $19.6 MILLION, AN INCREASE OF 7%​.‍EXPECTS FULL-YEAR 2018 CASH BURN IN RANGE OF $18 MILLION TO $22 MILLION​.QTRLY NET LOSS PER COMMON SHARE, BASIC AND DILUTED $0.24.FY2018 REVENUE VIEW $84.9 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Veracyte Announces Strategic Realignment And New Appointments To Advance Commercial Growth
Monday, 8 Jan 2018 07:30am EST 

Jan 8 (Reuters) - Veracyte Inc ::VERACYTE ANNOUNCES STRATEGIC REALIGNMENT AND NEW APPOINTMENTS TO ADVANCE COMMERCIAL GROWTH.- COMPANY REITERATES 2017 REVENUE AND CASH BURN GUIDANCE.- IS CONSOLIDATING CLINICAL, MEDICAL AND RESEARCH AND DEVELOPMENT FUNCTIONS INTO ONE DEPARTMENT.FY2017 EARNINGS PER SHARE VIEW $-0.87, REVENUE VIEW $71.3 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Veracyte posts Q3 loss per share $0.21
Monday, 6 Nov 2017 04:05pm EST 

Nov 6 (Reuters) - Veracyte Inc :Veracyte announces third quarter 2017 financial results.Q3 loss per share $0.21.Q3 revenue $17.5 million versus I/B/E/S view $19.5 million.Q3 earnings per share view $-0.23 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue $71 million to $72 million.Veracyte Inc - ‍narrowing range of its annual cash burn guidance to $25 to $26 million​.  Full Article

Veracyte reports Q2 loss per share $0.22
Monday, 31 Jul 2017 04:05pm EDT 

July 31 (Reuters) - Veracyte Inc -:Veracyte announces second quarter 2017 financial results.Q2 revenue $18.4 million versus I/B/E/S view $18.3 million.Sees FY 2017 revenue $76 million to $84 million.Qtrly loss per share $0.22.Veracyte Inc says reiterates its 2017 annual revenue guidance of $76 to $84 million and annual cash burn of $25 to $27 million.Q2 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S.FY2017 revenue view $77.0 million -- Thomson Reuters I/B/E/S.  Full Article

Veracyte says Anthem coverage for the Afirma gene expression classifier for use in thyroid cancer diagnosis
Thursday, 18 May 2017 12:18pm EDT 

May 18 (Reuters) - Veracyte Inc :Veracyte announces Anthem coverage for the Afirma® gene expression classifier for use in thyroid cancer diagnosis.Anthem Inc has issued positive coverage policy veracyte's Afirma Gene Expression Classifier (GEC) for use in thyroid cancer diagnosis.  Full Article

Veracyte announces Q1 revenue $16.4 million
Wednesday, 3 May 2017 04:05pm EDT 

May 3 (Reuters) - Veracyte Inc :Veracyte announces first quarter 2017 financial results.Q1 revenue $16.4 million versus I/B/E/S view $17.7 million.Sees FY 2017 revenue $76 million to $84 million.Veracyte Inc - Veracyte reiterates its 2017 annual revenue guidance of $76 to $84 million and annual cash burn of $25 to $27 million.Qtrly loss per share $0.24.Q1 revenue view $17.7 million -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S.FY2017 revenue view $79.9 million -- Thomson Reuters I/B/E/S.  Full Article